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The impact of contour variation on tumour control probability in anal cancer
Abstract
Background: While intensity modulated radiotherapy (IMRT) has been widely adopted for the treatment of
anal cancer (AC), the added contour complexity poses potential risks. This study investigates the impact
of contour variation on tumour control probability (TCP) when using IMRT for AC. Methods: Nine
Australian centres contoured a single computed tomography dataset of a patient with AC. The same
optimised template-based IMRT planning protocol was applied to each contour set to generate nine
representative treatment plans and their corresponding dose volume histograms. A geometric analysis
was performed on all contours. The TCP was calculated for each plan using the linear quadratic and
logitEUD model. Results: The median concordance index (CI) for the bladder, head and neck of femur,
bone marrow, small bowel and external genitalia was 0.94, 0.88, 0.84, 0.65 and 0.65, respectively. The
median CI for the involved nodal, primary tumour and elective clinical target volumes were 0.85, 0.77 and
0.71, respectively. Across the nine plans, the TCP was not significantly different. Variation in TCP between
plans increased as tumour cell load increased or radiation dose decreased. Conclusions: When using
IMRT for AC, contour variations generated from a common protocol within the limits of minor deviations
do not appear to have a significant impact on TCP. Contouring variations may be more critical with
increasing tumour cell load or reducing radiotherapy dose.
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The impact of contour variation on tumour
control probability in anal cancer
Michael P. Jones1,2* , Jarad Martin1,2, Kerwyn Foo3, Patrick Estoesta3, Lois Holloway4,5,6,7,8 and Michael Jameson4,5,6

Abstract
Background: While intensity modulated radiotherapy (IMRT) has been widely adopted for the treatment of anal
cancer (AC), the added contour complexity poses potential risks. This study investigates the impact of contour
variation on tumour control probability (TCP) when using IMRT for AC.
Methods: Nine Australian centres contoured a single computed tomography dataset of a patient with AC. The same
optimised template-based IMRT planning protocol was applied to each contour set to generate nine representative
treatment plans and their corresponding dose volume histograms. A geometric analysis was performed on all
contours. The TCP was calculated for each plan using the linear quadratic and logitEUD model.
Results: The median concordance index (CI) for the bladder, head and neck of femur, bone marrow, small bowel and
external genitalia was 0.94, 0.88, 0.84, 0.65 and 0.65, respectively. The median CI for the involved nodal, primary tumour
and elective clinical target volumes were 0.85, 0.77 and 0.71, respectively. Across the nine plans, the TCP was not
significantly different. Variation in TCP between plans increased as tumour cell load increased or radiation dose decreased.
Conclusions: When using IMRT for AC, contour variations generated from a common protocol within the limits of minor
deviations do not appear to have a significant impact on TCP. Contouring variations may be more critical with increasing
tumour cell load or reducing radiotherapy dose.
Keywords: Anal cancer, Chemo-radiotherapy, Squamous cell carcinoma, Tumour control probability

Background
Squamous cell carcinoma (SCC) of the anal canal (AC)
is an uncommon tumour with an increasing incidence
[1–3]. The treatment standard is organ sparing chemoradiotherapy (CRT) [4, 5], which achieves loco-regional
control in 63–86% [6–8] of patients but carries a risk of
significant acute and late toxicity [9].
In RTOG 0529, Intensity Modulated Radiotherapy
(IMRT) was shown to reduce acute toxicity and cause
fewer treatment interruptions compared with historical
controls [10]. It also highlighted the increased complexity
of IMRT. Remarkably, 81% of plans required revision and
46% required multiple revisions. Despite the provision
of a contouring atlas, most revisions were required
for incorrect contouring.
* Correspondence: mpjones85@gmail.com
1
School of Medicine and Public Health, University of Newcastle, Callaghan,
NSW, Australia
2
Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW,
Australia
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Contouring errors in IMRT based CRT increase locoregional recurrence in head and neck SCC [11, 12]. This
raises concerns for AC patients treated with IMRT by
inexperienced clinicians. Indeed, population based data
suggests AC patients treated at high volume centres
have improved survival [13].
The Trans-Tasman Radiation Oncology Group (TROG)
investigated IMRT as a new technology in the treatment
of AC as part of their Assessment of New Radiation
Oncology Technology and Treatments (ANROTAT) [14].
Their study compared the safety, clinical efficacy and cost
effectiveness of IMRT with three-dimensional conformal
radiation therapy (3DCRT).
The credentialing component of this study involved a
benchmarking assessment performed by nine Australian
centres. Each centre was provided a computed tomography (CT) dataset of a female patient with T3 N2 AC
(primary greater than 50 mm with involved mesorectal
and inguinal lymph nodes [LN]) to be treated with 54Gy
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Table 1 Tumour and organ at risk contoured volumes

Tumour control probability

Tumour Volumes

Organs at Risk

Primary clinical target volume to receive
54Gy (CTV54p)

Small bowel

Nodal clinical targe volume to receive
54Gy (CTV54n)

Bladder

Elective clinical target volume to receive
45Gy (CTV45)

External genitalia

Note: CTV45 included mesorectal,
pre-sacral, internal iliac, external iliac,
obturator and inguinal lymph nodes

Head and neck of femur
Bone marrow (ilium)

Dose volume histogram (DVH) data was extracted from
the treatment plans using CERR [17] and Matlab (The
Mathworks, Natick, USA). From the DVHs, CompPlan
[18] (open source software) calculated a TCP for each plan
using a linear quadratic and logitEUD model (shown in
Figs. 1 and 2). The models included a fraction-size effect
correction.
For the linear quadratic model where n is the number
of fractions and D’ is the total dose, an α/β ratio of
10Gy, α of 0.196 and N0 (number of initial clonogens) of
34,900 were used [19]. A sensitivity analysis investigated
the effect on TCP of increasing N0 and decreasing prescription dose.
For the logitEUD model where vi is a voxel, γ50 is the
slope of the dose response curve at D50 and Di is the
total dose delivered to each voxel, D50 values (dose required for a 50% probability of tumor control at 2 years)
for gross and microscopic disease were 42Gy and 30Gy,
respectively [19]. Given these values were taken from
curves fit to patients treated with CRT, the effect of concurrent chemotherapy was implicitly incorporated.

in 30 fractions. Centres were asked to contour clinical
target volumes (CTV) and organs at risk (OAR).
Having acquired these contours from TROG, we
sought to describe CTV and OAR contour variability as
well as model the impact of contour variation on
tumour control probability (TCP) when using IMRT for
AC.

Methods
Treatment planning

Each of the nine Australian centres participating in the
TROG TRP11.A (ANROTAT) Study B contoured OAR
and CTVs using a standard protocol (Table 1) and the
Australian Gastrointestinal Trials Group (AGITG) contouring atlas [15].
Varian’s Eclipse treatment planning system was used to
generate nine representative IMRT plans. An optimised
template-based IMRT planning protocol was initially
applied to each contour set. If dosimetric parameters were
not met in all plans, the template was adjusted and re-applied to all plans until all target volume and OAR constraints were met. Planning Target Volume (PTV)
coverage requirements and OAR constraints were based
on ANROTAT guidelines (Appendix).

Results
Geometric analysis

Table 2 shows the results of the OAR geometric analysis. There was close contour agreement for the bladder (median concordance index [CI] 0.94), head and
neck of femur (CI 0.88) and bone marrow (CI 0.84).
Greater contour variation was seen in the small bowel
(CI 0.65) and external genitalia (CI 0.65).
Table 3 shows the results of the tumour volume geometric analysis. Increasing contour variation was seen in
CTV54n (CI 0.85), CTV54p (CI 0.77) and CTV45 (CI 0.
71), respectively. The CTV45 and CTV54p contours are
shown in Fig. 3.
Tumour control probability

Geometric analysis

All observer generated contours were collated on a
single copy of the benchmarking CT dataset. A reference
contour was generated using the STAPLE [16] algorithm
in the Computational Environment for Radiotherapy
Research (CERR) [17]. In-house code was used to
analyse the geometric variation in contours. Metrics of
comparison included two volume overlap indices; concordance index (CI) and dice similarity coefficient
(DSC).

Fig. 1 The linear quadratic model

The TCP for CTVs are shown in Table 3. Using the linear quadratic model, the median TCP for CTV45,
CTV54p and CTV54n was 0.84 (standard deviation
[SD] 0.18), 0.94 (SD 0.11) and 1.00 (SD 0.00), respectively. Using the logitEUD model, the median TCP for
CTV45, CTV54p and CTV54n was 0.60 (SD 0.04), 0.52
(SD 0.02) and 0.53 (SD 0.02).
Sensitivity analysis of the linear quadratic model
revealed that the TCP reduced as tumour cell load increased (Fig. 4a) but variation in TCP between plans
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Fig. 2 The logitEUD model

increased (Fig. 4b). Likewise, as radiation dose decreased, TCP reduced (Fig. 4c) and variation in TCP
between plans increased (Fig. 4d).

guidelines exist. While United Kingdom guidelines have
been proposed [24], until consensus guidelines are formalised, variation in external genitalia contours is likely
to persist.
For the development and implementation of evidenced
based OAR dose constraints, consistent contouring is imperative [25, 26]. This is particularly true in AC IMRT where
the proximity of OAR and tumour volumes often requires a
compromise between adequate coverage and safety.

Tumour volume contour variation

Discussion
Organ at risk contour variation

Our results reveal while there was good inter-observer
agreement for the bladder (CI: 0.94), head and neck of
femur (CI 0.88) and bone marrow (CI: 0.84), there was
significant contour variation in the small bowel (CI 0.65)
and external genitalia (CI: 0.65).
For the small bowel, inclusion of the large bowel, iliac
vessels, ovaries, peritoneum and muscle were common
contouring errors. The lack of oral contrast may have
contributed to these inaccuracies. Oral contrast delivered 1 h prior to CT simulation is usually recommended
to improve small bowel identification [20].
Controversy persists regarding the optimal bowel contouring technique. No consensus was reached by RTOG
[20] and QUANTEC [21] list dose constraints for both
bowel loops and a bowel bag. While a bowel bag
accounts for the mobility of viscera and simplifies OAR
contouring, it may have limitations for post-surgical
patients and in capturing inferior motion [22].
Misidentification of the small (60%) and large (45%)
bowel was also common in plans submitted to RTOG
0529 [23]. However, accuracy of the external genitalia
contours was not reported. In fact the RTOG pelvic
OAR contouring guidelines do not include instructions
for contouring external genitalia [20] and no consensus
Table 2 Organ at risk geometric analysis

Despite being provided gross tumour volumes (GTV),
variations in the protocoled CTV expansions were seen:
CTV54p (CI 0.77), CTV54n (CI 0.85) and CTV45 (CI 0.
71). Unsurprisingly, the greatest variation was seen in
the CTV45 volumes. These are the largest and the least
influenced by the GTV. Incorrect elective nodal contouring was also common in RTOG 0529 where errors
were seen in the mesorectum (55%), pre-sacral (43%), inguinal (33%) and iliac nodal groups (31%).
The greatest discrepancies in the CTV45 volumes were
in the anterior direction with variable expansion into the
uterus and bladder. The AGITG guidelines recommend
an internal margin expansion of 1 cm into the bladder
and uterus to account for bladder volume variation [15].
The greatest discrepancies in the CTV54p volumes
were also in the anterior direction with variable expansion into the vagina and genitalia. Some have highlighted
the risk of genital relapse when IMRT is used to achieve
genital sparing [27]. While this has been challenged
more recently [28], we emphasise the priority of adequate tumour coverage over genital sparing and stress
the importance of accurate multi-modality baseline
imaging to help optimally define the extent of disease.
Contouring atlases for anorectal volumes have been
shown to reduce inter-observer variability [29], however,
atlases were available to observers in both the RTOG and
TROG studies. Perhaps this variation can be attributed to
clinicians coming to terms with a new technique.

Organs at Risk

Stats

CI

DSC

Volume (cm3)

Small bowel

Median

0.65

0.79

543.22

Table 3 Tumour control probability and tumour volume
geometric analysis

Range

0.12

0.10

132.37

Volume

Stats

TCP (LQ)

TCP (Logit)

CI

DSC

Median

0.94

0.97

156.37

Volume
(cm3)

SD

0.01

0.01

6.43

CTV45

Median

0.84

0.60

0.71

0.82

1299.38

Median

0.65

0.79

130.61

SD

0.18

0.04

0.13

0.10

190.64

CTV54p

Median

0.94

0.52

0.77

0.86

458.83

SD

0.11

0.02

0.17

0.13

132.92

CTV54n

Median

1.00

0.53

0.85

0.89

37.92

SD

0.00

0.02

0.26

0.21

7.69

Bladder

External genitalia

Head and neck of femur

Bone marrow (ilium)

SD

0.19

0.17

65.47

Median

0.88

0.93

202.29

SD

0.06

0.03

23.73

Median

0.84

0.91

371.61

SD

0.06

0.03

22.62

SD: standard deviation, CI: concordance index, DSC: dice similarity coefficient

CTV45: elective clinical targe volume, CTV54p: primary clinical target volume,
CTV54n: nodal clinical target volume, SD: standard deviation, CI: concordance
index, DSC: dice similarity coefficient
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Fig. 3 Tumour volumes contoured by the nine participating centres. Left: Primary clinical target volumes (CTV54p), Right: Elective clinical targe
volumes (CTV45)

A literature review identified guidelines, teaching, autocontouring and multi-modality imaging as interventions
that reduce inter-observer variability in contour delineation
[30]. Online teaching and contouring workshops are now
offered by international cancer societies and clinicians can
have their volumes peer reviewed at their centre and
through participation in clinical trials incorporating radiotherapy quality assurance.
Tumour control probability

IMRT is the treatment of choice for AC [31]. It
enhances the therapeutic window by reducing dose to

OAR and resultant acute toxicity [23]. Fewer treatment
breaks for toxicity are required and it offers the prospect
of safe dose escalation for large tumours. However, AC
contouring is complex and considerable variation exists
in target volume delineation [29, 31].
We have shown that minor contour variations generated from a common protocol do not translate into
significant differences in TCP. By applying a templatebased IMRT planning protocol, we isolated the impact
of contour variation on TCP. Further TCP variability
would be expected should centres develop their own
treatment plans or employ different treatment doses.

Fig. 4 Sensitivity analyses. a: Tumour control probability with changing N0, b: variation in tumour control probability between plans with changing N0,
c: tumour control probability with changing dose, d: variation in tumour control probability between plans with changing dose. TCP = Tumour Control
Probability, SD = Standard Deviation, N 0 = number of initial clonogens, Gy = Gray, CTV54p = Primary clinical target volume to receive 54Gy,
CTV54n = Nodal clinical targe volume to receive 54Gy, CTV45 = Elective clinical target volume to receive 45Gy

Jones et al. Radiation Oncology (2018) 13:97

Contours for this study were generated from a common contouring guideline [14]. Contouring guidelines
lead to greater inter-observer agreement [32] and the
provision of an anorectal contouring atlas has been
shown to increase TCP and reduce normal tissue complication probability (NTCP) [29].
GTV contours were supplied in the TROG study
which may have reduced CTV variation. Inaccurate
GTV delineation occurred in 21% of plans submitted to
RTOG 0529 [23]. Target volume delineation is more
accurate with the use of co-registered Positron Emission
Tomography (PET) and Magnetic Resonance Imaging
(MRI) and is recommended for treatment planning [31].
PET is recommended to identify lymph nodes requiring
inclusion in the GTV [33].
Sensitivity analysis

We investigated the influence of prescription dose and
N0 (number of initial clonogens) on the TCP predicted
by the linear quadratic model. Increasing N0 led to a
reduction in TCP (Fig. 4a) and an increase in the TCP
variation between plans (Fig. 4b). Decreasing dose led to
a reduction in TCP (Fig. 4c) and increase in TCP variation between plans (Fig. 4d).
While the influence of dose and N0 on the absolute
TCP is not surprising, the effect on TCP variation is
quite interesting. It suggests contour variations become
more critical as one moves down the dose response
curve either by increasing tumour cell load or reducing
dose. These are important insights for radiation dose deescalation trials such as ACT 3 and 4 [34] and highlights
the central role real-time radiotherapy quality assurance
should play in these studies.
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While a NTCP assessment was explored, this was
abandoned due to a lack of reliable radiobiological parameters in the literature. The principle benefit of IMRT
is reduced OAR dose, avoidance of toxicity induced
treatment gaps and the prospect of safe dose escalation for
larger tumours. To achieve this, tumour volumes must balance adequate coverage of at risk sites with toxicity risk.
The ACT 3–5 [34] studies will provide valuable insights into the radiation dose response curve for AC.
The incorporation of prognostic factors other than stage
such as human papilloma virus status could help further
refine this relationship [36]. Treatment adaptation represents another promising approach and may ultimately
provide the best means of individualising treatment [37].

Conclusions
In the context of a clinical study, with the dose and
parameters used, minor contour variations generated
from a common guideline did not significantly impact
TCP. With increasing tumour cell load or reducing RT
dose, contour variations may be more critical.
Appendix

Volume

Constraint

PTV 45

D95 ≥ 40.5Gy
D98 ≥ 36Gy
D98 ≥ 36Gy

PTV 54

D98 ≥ 43.2Gy
D2% ≤ 62.1Gy
Small bowel

Limitations and future directions

In radiation therapy, TCP models have traditionally been
limited to the relative comparison of treatment plans
rather than their absolute predictive power. Indeed, the
difference in tumour control estimated by the two
models used in our study highlights the dangers of over
interpreting TCP results or using them to inform radiotherapy dose selection.
That contours were completed in the context of a trial
using a common protocol with a GTV already provided
is a shortcoming of this study potentially limiting its
applicability to the wider community. Our results are
likely to underestimate contour variation and do not
capture the effect of radiotherapy plan generation.
Our study aim was to isolate the impact of contour
variation on TCP. While we appreciate there is manual
bias in planning [35], it is out of the scope of this study.
We tried to mitigate against this by using a single planner and single patient anatomy, deploying a class solution beam arrangement, objectives and priorities.

D95 ≥ 48.6

V30Gy ≤ 200 cm3
V35Gy ≤ 150 cm3
V45Gy ≤ 20 cm3
V50Gy = 0 cm3

Femoral heads

V30Gy ≤ 50%
V40Gy ≤ 35%
V44Gy ≤ 5%

Iliac crest

V30Gy ≤ 50%
V40Gy ≤ 35%
V50Gy ≤ 5%

External genitalia

V20Gy ≤ 50%
V30Gy ≤ 35%
V40Gy ≤ 5%

Bladder

V35Gy ≤ 50%
V40Gy ≤ 35%
V50Gy ≤ 5%

Jones et al. Radiation Oncology (2018) 13:97
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